Cargando…
IL‐7–Mediated IL‐7R‐JAK3/STAT5 signalling pathway contributes to chemotherapeutic sensitivity in non–small‐cell lung cancer
OBJECTIVES: The chemotherapy drug resistance is a major challenge for non‐small‐cell lung cancer (NSCLC) treatment. Combination of immunotherapy and chemotherapy has shown promise for cancer. The goal of this study was to evaluate the anti‐tumour efficacy of interleukin‐7 (IL‐7) combining cisplatin...
Autores principales: | Shi, Lin, Xu, Zhaozhong, Yang, Qiong, Huang, Yuanyuan, Gong, Yuxin, Wang, Fang, Ke, Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6869130/ https://www.ncbi.nlm.nih.gov/pubmed/31599032 http://dx.doi.org/10.1111/cpr.12699 |
Ejemplares similares
-
Oncogenic Cooperation Between IL7R-JAK-STAT Pathway Mutations
por: Lodewijckx, Inge, et al.
Publicado: (2021) -
Regulation of TRPM7 Function by IL-6 through the JAK2-STAT3 Signaling Pathway
por: Liu, Aifen, et al.
Publicado: (2016) -
IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status
por: Ceausu, Andra, et al.
Publicado: (2019) -
The Role of IL-7 and IL-7R in Cancer Pathophysiology and Immunotherapy
por: Wang, Chunli, et al.
Publicado: (2022) -
Gene variation in IL-7 receptor (IL-7R)α affects IL-7R response in CD4+ T cells in HIV-infected individuals
por: Hartling, Hans Jakob, et al.
Publicado: (2017)